[The 2010 news: highlights of the ASCO-GU, UAE, ASCO, AUA congress…]
Related Experiment Video
Updated: Jun 3, 2026
Robotics in Surgery: A Modular Robotic Platform Driven Gastric Wedge Resection
Published on: February 7, 2025
T Bessede1, P Bigot, Y Neuzillet
1Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France.
Abstract:
The main news in kidney oncourology are PET CaIX as potential new diagnostic and monitoring tool, the lack of progress in terms of drug combination therapy, the sequential approach remains the standard, lack of progress also in selecting good candidates for immunotherapy, the possible benefit of nephrectomy, that only the CARMENA study will determine, and the emergence of determining the risk of recurrence after nephrectomy using genomic study. Concerning non muscle invasive bladder cancer, endoscopic diagnosis seems improved by the NBI and immunofluorescence. The staging of pT1 tumors may evolve. The poor prognosis of Cis was stressed. The indication of cystectomy for BCG failure has been clarified. For muscle invasive bladder cancer, the prognostic impact of lympho-vascular invasion was reported. The importance of an extended lymphadenectomy has been demonstrated. In cases of symptomatic bone metastases, zoledronic acid increased overall survival. An analysis of performance and drawbacks of radio-hormonotherapy was performed. The denosumab and zoledronic acid were compared in prevention of bone loss during androgen deprivation. The antagonists of LH-RH, the cabazitaxel and immunotherapies could be part of the therapies for advanced prostate cancer. For penile cancer treatment, in case of suspicious nodes, ultrasound guided cytopuncture is useful. For testis cancer, the recurrence rate for stage I seminoma has been estimated, at 15%. The PET-scan is also helpful to assess the nodal tumoral spread during the staging and the follow-up of patients treated by chemotherapy.
Insights
Advances in kidney cancer include PET CaIX imaging and genomic risk assessment. Bladder cancer updates cover diagnosis, staging, and treatment for BCG failure. Prostate cancer therapies and penile/testis cancer management are also discussed.
Area of Science:
- Oncourology
- Nephrology
- Urology
Context:
- Kidney cancer research highlights PET CaIX as a diagnostic tool and genomic studies for recurrence risk post-nephrectomy.
- Non-muscle invasive bladder cancer (NMIBC) diagnosis may improve with NBI and immunofluorescence, with evolving pT1 staging and clarified cystectomy indications for BCG failure.
- Muscle-invasive bladder cancer (MIBC) research emphasizes lympho-vascular invasion prognosis and extended lymphadenectomy benefits.
Purpose:
- To review recent advancements and ongoing research in kidney, bladder, prostate, penile, and testis cancers.
- To highlight emerging diagnostic tools, therapeutic strategies, and prognostic indicators across various urologic malignancies.
- To provide an update on the standard of care and future directions in oncourology.
Summary:
- Kidney cancer news includes PET CaIX potential, lack of progress in combination therapy, and genomic risk stratification. NMIBC diagnosis and staging are improving, with clarified indications for cystectomy. MIBC prognosis is linked to lympho-vascular invasion and lymphadenectomy extent.
- For advanced prostate cancer, LH-RH antagonists, cabazitaxel, and immunotherapies are considered. Penile cancer diagnosis benefits from ultrasound-guided cytopuncture for suspicious nodes. Testis cancer updates include seminoma recurrence rates and PET-scan utility.
- Bone metastases management shows zoledronic acid improving survival, with comparisons between denosumab and zoledronic acid for bone loss prevention during androgen deprivation. Radio-hormonotherapy performance is also analyzed.
Impact:
- These updates inform clinical practice and future research directions in managing urologic cancers.
- Improved diagnostic accuracy and risk stratification can lead to more personalized treatment strategies.
- The findings underscore the importance of novel imaging, genomic analysis, and refined therapeutic approaches in improving patient outcomes.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Standards of Care II
01:28International Nursing Organizations II
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:22Standards of Care I
01:17Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources, and lay...